Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent
- 1 June 2002
- journal article
- case report
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 46 (6) , 945-947
- https://doi.org/10.1067/mjd.2002.120627
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Practice Guidelines for Diseases Caused by AspergillusClinical Infectious Diseases, 2000
- Echinocandins and pneumocandins--a new antifungal class with a novel mode of actionJournal of Antimicrobial Chemotherapy, 1997
- Clinical presentation of invasive aspergillosisMycoses, 1997
- Infections in solid-organ transplant recipientsClinical Microbiology Reviews, 1997
- OPPORTUNISTIC INFECTIONS IN ONCOLOGIC PATIENTSHematology/Oncology Clinics of North America, 1996
- CUTANEOUS ASPERGILLOSISDermatologic Clinics, 1996
- Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesisAntimicrobial Agents and Chemotherapy, 1994
- Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthaseAntimicrobial Agents and Chemotherapy, 1994
- Synthesis and Antifungal Activity of Novel Cationic Pneumocandin Bo DerivativesJournal of Medicinal Chemistry, 1994
- Opportunistic fungal infections in immunocompromised hostsJournal of the American Academy of Dermatology, 1989